GlycoBien®
INDICATION: Diabetes
GlycoBien® CR is a novel once-daily oral hypoglycemic drug for lowering blood sugar and reduction of glucose spikes.
Discover GlycoBien®
Overview
GlycoBien® is designed to provide first-line therapy for both prediabetics and newly diagnosed Type 2 diabetic patients.
Phase
GlycoBien® CR is currently in Phase II clinical trial.
US Market ($B USD)
The estimated market for GlycoBien® in the United States is $8 Billion USD.
Global Market ($B USD)
The estimated market for GlycoBien® globally is $10 Billion USD.